<DOC>
	<DOCNO>NCT02171468</DOCNO>
	<brief_summary>To investigate compare pharmacokinetics , safety pharmacodynamics dabigatran etexilate follow oral administration multiple dos ( 110 mg 150 mg b.i.d. , 7 day ) healthy male subject Japanese Caucasians</brief_summary>
	<brief_title>Pharmacokinetics , Safety Pharmacodynamics After Multiple Oral Doses Dabigatran Etexilate Capsule Healthy Japanese Caucasian Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Japanese Caucasian healthy male subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate body temperature ) , 12lead electrocardiogram , clinical laboratory test No find clinical relevance No evidence clinically relevant concomitant disease Caucasian subject welldefined Caucasian population , parent Caucasians , subject understand subject information inform consent English subject live 8 less 8 year Japan 2 . Age : ≥20 ≤45 year 3 . Body mass index ( BMI ) : ≥18.5 ≤29.9 kg/m2 4 . Signed date write informed consent admission trial site 1 . Current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Subject use adequate form contraception time first dose Day 1 endof study examination 3 . Current diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder 4 . History clinically significant orthostatic hypotension , clinically significant current past fainting spell blackouts 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant safety assessment judge investigator ( exclude asymptomatic seasonal rhinitis/hay fever ) bleed disorder include prolonged habitual bleeding hematologic diseases cerebral bleeding ( e.g . car accident ) concussion ( head trauma result injure brain ) without loss consciousness 7 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives , whichever short , respective drug prior administration trial 8 . Use aspirin ( include overthecounter medication ) , antipletelet agent like ticlopidine dipyridamole , chronic administration nonsteroidal antiinflammatory drug , coumadin like anticoagulant , chronic use corticosteroid , heparin fibrinolytic agent within 28 day prior administration endofstudy examination 9 . Participation another trial investigational drug within 3 month prior administration endofstudy examination 10 . Smoker ( &gt; 10 cigarettes/day inability refrain smoke trial ) 11 . Alcohol abuse ( 60 g/day ; confirm interview ) 12 . Drug abuse ( confirm interview ) 13 . Blood donation ( 100 mL 3 month prior screen blood donation screen endofstudy examination ) 14 . Excessive physical activity ( within 7 day prior first drug administration endofstudy examination ) 15 . Any laboratory value outside reference range clinical relevance 16 . Known hypersensitivity investigational drug excipients 17 . Subject judge ineligible investigator subinvestigator 18 . History familial bleeding disorder 19 . Thrombocytes &lt; 15 x 10**4 /microL</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>